Skip to content
Sign in
Artwork for Conversations in Drug Development
ScienceLife SciencesHealth & FitnessMedicine

Conversations in Drug Development

Boyds

Welcome to Conversations in Drug Development, brought to you by the team at Boyds for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development. This podcast series features candid conversations from the expert team at Boyds, who are at the forefront of cutting-edge science and drug development in the pharmaceutical and biotechnology sector.

Play
Open in
  • 22 episodes
  • every few months
  • Avg 29 min
  • English

Episodes 22

NewestOldestLongest
All2Unplayed2In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • #8
    May 21, 2024 · 19 min

    The Use of ATMPs in Oncology Clinical Trials

    How can phase I studies with ATMPs address unmet needs in oncology and what are the challenges? In this episode of Conversations in Drug Development, Dr Katherine Bowen is joined by Pharmaceutical Physician, Dr Harriet Gray Stephens, to delve into the complexities of phase I oncology studies involving advanced therapy medicinal products (ATMPs). Join us as we discuss the unique challenges of ATMPs, such as their different benefit-risk profiles compared to traditional therapies, and the need for innovative dose escalation and efficacy evaluation methods as well as the potential of ATMPs to meet unmet needs in cancer treatment.

    • Transcript
    • Chapters
  • #7
    Apr 25, 2024 · 24 min

    How are GMO Regulations Impacting Clinical Development in Europe?

    In this episode of Conversations in Drug Development, our host Harriet Edwards, is joined by Director of Regulatory Affairs, Dr Sabine Ruehle, to discuss the challenges of navigating genetically modified organism (GMO) regulations in clinical trials within Europe. This discussion helps decipher the nuanced environment of GMOs and their associated risks unique within the European framework. Join us as we explore the outdated definition of GMOs, the complexities of their classification, and the impact of genome editing technologies.

    • Transcript
    • Chapters
Showing 21–22 of 22 episodes